title: Update on diffuse alveolar hemorrhage and pulmonary vasculitis.
abstract: Diffuse alveolar hemorrhage is a clinical syndrome that can be a manifestation of multiple different causes. Identification of the underlying etiology is of utmost importance and dictates treatment. Pulmonary vasculitis including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a common cause of diffuse alveolar hemorrhage. For AAV, treatment includes induction followed by maintenance therapy. Rituximab has an increasing role in the treatment of AAV.
authors.affiliation: Department of Internal Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
authors.forename: Megan L
authors.initials: ML
authors.lastname: Krause
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Cartin-Ceba
authors.forename: Ulrich
authors.initials: U
authors.lastname: Specks
authors.forename: Tobias
authors.initials: T
authors.lastname: Peikert
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000628:therapy; D016736:Antiphospholipid Syndrome / Q000150:complications; D003937:Diagnosis, Differential; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006470:Hemorrhage / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D011650:Pulmonary Alveoli / Q000098:blood supply*; D014657:Vasculitis / Q000150:complications*